C5DC/C8 ratio for GA1 screening

This test measures the ratio of two acylcarnitines in blood: glutarylcarnitine (C5DC) and octanoylcarnitine (C8). It is part of an acylcarnitine profile that helps evaluate how your body breaks down certain amino acids and fats. The ratio is often used as a marker for glutaric acidemia type I (GA1), a rare inherited condition that affects energy metabolism.

Your sample may be collected as a dried blood spot, serum, or plasma, depending on the laboratory. The ratio provides a more stable signal than a single marker in some situations, which can improve interpretation alongside other tests.

Healthcare providers use this ratio to assess the likelihood of GA1, especially in newborn screening or when there are symptoms like low muscle tone, movement problems, or episodes of acute illness with neurological concerns. Early identification allows prompt nutrition and metabolic care, which can help prevent serious complications.

The ratio can also help interpret an abnormal acylcarnitine profile by accounting for individual differences and testing conditions. If the result suggests GA1, follow-up testing usually includes urine organic acids, molecular testing of the GCDH gene, enzyme studies when available, and evaluation by a metabolic specialist.

Your result is interpreted together with the overall acylcarnitine profile, your clinical picture, and sometimes repeat testing. A higher-than-expected ratio can point toward GA1, but it is not a diagnosis on its own. Other conditions, sample timing, or treatments can influence acylcarnitines, so confirmatory tests are important before any care decisions are made.

If your result raises concern, your clinician may arrange additional tests and discuss diet, carnitine supplementation, and sick-day management plans. If the result is within the expected range and you have no symptoms or risk factors, no further action may be needed. Your care team will guide next steps based on your age, health status, and any family history.